PRO Journal SA-CME activity for July-August, 2019 (Volume 9, Issue 4) will help practitioners to identify planning uncertainties and elements required for unambiguous reporting. 

The definition of the clinical target volume (CTV) is becoming the weakest link in the radiotherapy chain. In this session we will first review some of the challenges of the standard CTV definition process (the "art").

Many practices are experiencing increasing numbers of cases for which irradiation of previously treated areas is required. This requires careful consideration of a range of radiobiological, dose discounts for prior treatments, clinical practice flow, documentation and treatment planning issues.

IJROBP Journal SA-CME activity for November 15, 2018 (Volume 102, Issue 2) explains the goals of radiomics at a fundamental level and the techniques in current use. It also advises caution in applying these tools as predictors of response in oncology.

The definition of the clinical target volume (CTV) is becoming the weakest link in the radiotherapy chain. In this session we will first review some of the challenges of the standard CTV definition process (the "art").

Many practices are experiencing increasing numbers of cases for which irradiation of previously treated areas is required. This requires careful consideration of a range of radiobiological, dose discounts for prior treatments, clinical practice flow, documentation and treatment planning issues.

IJROBP Journal SA-CME activity for August 1, 2018 (Volume 101, Issue 5) provides practitioners with the knowledge needed to discuss emerging MR techniques for radiotherapy planning and response assessment.

Recent advances in brachytherapy techniques have included the use of volumetric imaging (CT, MRI) for target delineation, ultrasound-guided applicator placement, personalized implantation of interstitial catheters, inverse planning dose optimization algorithm and model-based dose calculation meth

IJROBP Journal SA-CME activity for October 1, 2017 (Volume 99, Issue 2) explores the limitations of intensity modulated proton therapy as used to treat a variety of malignancies.